BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 11, 2010
 |  BC Week In Review  |  Company News  |  Deals

Trimeris, Novartis, Roche deal

Trimeris will no longer be responsible for $18.7 million owed to Roche related to marketing expenses for Fuzeon enfuvirtide as part of an amended 1999 deal in which the companies were developing the viral fusion inhibitor peptide analog based on...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >